Bristol-Myers Squibb Dividends and Buybacks
Dividend criteria checks 5/6
Bristol-Myers Squibb is a dividend paying company with a current yield of 5.17%.
Key information
5.2%
Dividend yield
0.002%
Buyback Yield
| Total Shareholder Yield | 5.2% |
| Future Dividend Yield | 5.5% |
| Dividend Growth | 5.5% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | 91% |
Recent dividend and buyback updates
Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.62
Dec 29
Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year
Dec 15Recent updates
Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence
May 27We Think Bristol-Myers Squibb's (NYSE:BMY) Robust Earnings Are Conservative
May 05Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession
Apr 22Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold
Mar 25Bristol-Myers Squibb: Why I'm Still Bullish
Mar 18
Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value
Total Revenues: $12.3 billion, an 8% increase from the same period in 2023.Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Feb 21Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
Feb 07Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain
Jan 31Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.62
Dec 29Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued
Dec 20Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year
Dec 15Revenues Not Telling The Story For Bristol-Myers Squibb Company (NYSE:BMY)
Nov 275 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)
Nov 25Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren
Oct 28Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon
Oct 06Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Sep 27Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows
Sep 06Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues
Aug 15Bristol-Myers Squibb: A Potential Comeback In Healthcare
Aug 06Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point
Jul 27Bristol Myers Squibb: The More It Drops, The More I Buy
Jul 16Stability and Growth of Payments
Fetching dividends data
Stable Dividend: BMY's dividends per share have been stable in the past 10 years.
Growing Dividend: BMY's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| Bristol-Myers Squibb Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (BMY) | 5.2% |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.8% |
| Industry Average (Pharmaceuticals) | 2.7% |
| Analyst forecast (BMY) (up to 3 years) | 5.5% |
Notable Dividend: BMY's dividend (5.17%) is higher than the bottom 25% of dividend payers in the US market (1.56%).
High Dividend: BMY's dividend (5.17%) is in the top 25% of dividend payers in the US market (4.78%)
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (91.4%), BMY's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (38.6%), BMY's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/04 09:43 |
| End of Day Share Price | 2025/06/04 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bristol-Myers Squibb Company is covered by 47 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Charles Butler | Barclays |